;PMID: 10071245
;source_file_756.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..147] = [t:42..147]
;2)section:[e:151..205] = [t:151..205]
;3)section:[e:209..281] = [t:209..281]
;4)sentence:[e:285..495] = [t:285..495]
;5)sentence:[e:496..646] = [t:496..646]
;6)sentence:[e:647..779] = [t:647..779]
;7)sentence:[e:780..907] = [t:780..907]
;8)sentence:[e:908..1093] = [t:908..1093]
;9)section:[e:1097..1142] = [t:1097..1142]

;section 0 Span:0..37
;Virchows Arch  1999 Feb;434(2):117-20
(SEC
  (FRAG (NNP:[0..8] Virchows) (NNP:[9..13] Arch) (CD:[15..19] 1999)
        (.:[20..28] Feb;434-LRB-) (CD:[28..29] 2) (-RRB-:[29..30] -RRB-)
        (CD:[30..34] :117) (::[34..35] -) (CD:[35..37] 20)))

;sentence 1 Span:42..147
;In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with
; their malignant potential.
;[45..69]:malignancy:"serous ovarian neoplasms"
;[87..93]:gene-rna:"Ki-ras"
(SENT
  (S-HLN
    (PP-LOC (IN:[42..44] In)
      (NP (JJ:[45..51] serous) (JJ:[52..59] ovarian) (NNS:[60..69] neoplasms)))
    (NP-SBJ
      (NP (DT:[70..73] the) (NN:[74..83] frequency))
      (PP (IN:[84..86] of)
        (NP (NN:[87..93] Ki-ras) (NNS:[94..103] mutations))))
    (VP (VBZ:[104..114] correlates)
      (PP-CLR (IN:[115..119] with)
        (NP (PRP$:[121..126] their) (JJ:[127..136] malignant)
            (NN:[137..146] potential))))
    (.:[146..147] .)))

;section 2 Span:151..205
;Haas CJ, Diebold J, Hirschmann A, Rohrbach H, Lohrs U.
(SEC
  (FRAG (NNP:[151..155] Haas) (NNP:[156..158] CJ) (,:[158..159] ,)
        (NNP:[160..167] Diebold) (NNP:[168..170] J,) (NNP:[171..181] Hirschmann)
        (NNP:[182..183] A) (,:[183..184] ,) (NNP:[185..193] Rohrbach)
        (NNP:[194..195] H) (,:[195..196] ,) (NNP:[197..202] Lohrs)
        (NNP:[203..205] U.)))

;section 3 Span:209..281
;Institute of Pathology, Ludwig-Maximilians-Universitat, Munich, Germany.
(SEC
  (FRAG (NNP:[209..218] Institute) (IN:[219..221] of) (NNP:[222..231] Pathology)
        (,:[231..232] ,) (NNP:[233..239] Ludwig) (::[239..240] -)
        (NNP:[240..251] Maximilians) (::[251..252] -)
        (NNP:[252..263] Universitat) (,:[263..264] ,) (NNP:[265..271] Munich)
        (,:[271..272] ,) (NNP:[273..280] Germany) (.:[280..281] .)))

;sentence 4 Span:285..495
;We analysed 44 tissue samples from serous ovarian neoplasms of different 
;malignant potential for Ki-ras mutations by denaturing gradient gel 
;electrophoresis (DGGE) and direct sequencing after microdissection.
;[320..344]:malignancy:"serous ovarian neoplasms"
;[383..389]:gene-rna:"Ki-ras"
(SENT
  (S
    (NP-SBJ (PRP:[285..287] We))
    (VP (VBD:[288..296] analysed)
      (NP
        (NP (CD:[297..299] 44) (NN:[300..306] tissue) (NNS:[307..314] samples))
        (PP (IN:[315..319] from)
          (NP
            (NP (JJ:[320..326] serous) (JJ:[327..334] ovarian)
                (NNS:[335..344] neoplasms))
            (PP (IN:[345..347] of)
              (NP (JJ:[348..357] different) (JJ:[359..368] malignant)
                  (NN:[369..378] potential))))))
      (PP-PRP (IN:[379..382] for)
        (NP (NN:[383..389] Ki-ras) (NNS:[390..399] mutations)))
      (PP-MNR (IN:[400..402] by)
        (NP
          (NP
            (NP
              (NML (VBG:[403..413] denaturing) (NN:[414..422] gradient))
              (NN:[423..426] gel) (NN:[428..443] electrophoresis))
            (NP (-LRB-:[444..445] -LRB-) (NN:[445..449] DGGE)
                (-RRB-:[449..450] -RRB-)))
          (CC:[451..454] and)
          (NP
            (NP (JJ:[455..461] direct) (NN:[462..472] sequencing))
            (PP-TMP (IN:[473..478] after)
              (NP (NN:[479..494] microdissection)))))))
    (.:[494..495] .)))

;sentence 5 Span:496..646
;Point  mutations at codon 12 were found in 7 of 20 tumours of low malignant
;potential  (LMP) (35%) and in 2 of 6 well-differentiated carcinomas (33%).
;[496..512]:variation-type:"Point  mutations"
;[516..524]:variation-location:"codon 12"
;[547..581]:malignancy:"tumours of low malignant potential"
;[584..587]:malignancy:"LMP"
;[609..639]:malignancy:"well-differentiated carcinomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[496..501] Point) (NNS:[503..512] mutations))
      (PP-LOC (IN:[513..515] at)
        (NP (NN:[516..521] codon) (CD:[522..524] 12))))
    (VP (VBD:[525..529] were)
      (VP (VBN:[530..535] found)
        (NP-1 (-NONE-:[535..535] *))
        (PP-LOC
          (PP (IN:[536..538] in)
            (NP
              (NP (CD:[539..540] 7))
              (PP (IN:[541..543] of)
                (NP
                  (NP (CD:[544..546] 20) (NNS:[547..554] tumours))
                  (PP (IN:[555..557] of)
                    (NP
                      (NP (JJ:[558..561] low) (JJ:[562..571] malignant)
                          (NN:[572..581] potential))
                      (NP (-LRB-:[583..584] -LRB-) (NN:[584..587] LMP)
                          (-RRB-:[587..588] -RRB-))))))
              (PRN (-LRB-:[589..590] -LRB-)
                (NP (CD:[590..592] 35) (NN:[592..593] %))
                (-RRB-:[593..594] -RRB-))))
          (CC:[595..598] and)
          (PP (IN:[599..601] in)
            (NP
              (NP (CD:[602..603] 2))
              (PP (IN:[604..606] of)
                (NP (CD:[607..608] 6)
                  
                  (ADJP (RB:[609..613] well) (HYPH:[613..614] -)
                        (JJ:[614..628] differentiated))
                  (NNS:[629..639] carcinomas)))
              (PRN (-LRB-:[640..641] -LRB-)
                (NP (CD:[641..643] 33) (NN:[643..644] %))
                (-RRB-:[644..645] -RRB-)))))))
    (.:[645..646] .)))

;sentence 6 Span:647..779
;In contrast, no  mutations were detected in the 11 poorly differentiated
;ovarian carcinoma  samples or in the 7 serous cystadenomas.
;[698..737]:malignancy:"poorly differentiated ovarian carcinoma"
;[759..778]:malignancy:"serous cystadenomas"
(SENT
  (S
    (PP (IN:[647..649] In)
      (NP (NN:[650..658] contrast)))
    (,:[658..659] ,)
    (NP-SBJ-1 (DT:[660..662] no) (NNS:[664..673] mutations))
    (VP (VBD:[674..678] were)
      (VP (VBN:[679..687] detected)
        (NP-1 (-NONE-:[687..687] *))
        (PP-LOC
          (PP (IN:[688..690] in)
            (NP (DT:[691..694] the) (CD:[695..697] 11)
              
              (ADJP (RB:[698..704] poorly) (JJ:[705..719] differentiated))
              (JJ:[720..727] ovarian) (NN:[728..737] carcinoma)
              (NNS:[739..746] samples)))
          (CC:[747..749] or)
          (PP (IN:[750..752] in)
            (NP (DT:[753..756] the) (CD:[757..758] 7)
               (JJ:[759..765] serous) (NNS:[766..778] cystadenomas))))))
    (.:[778..779] .)))

;sentence 7 Span:780..907
;The frequency of Ki-ras mutations in  serous ovarian tumours seems to
;correlate with the malignant potential of the  neoplasms.
;[797..803]:gene-rna:"Ki-ras"
;[818..840]:malignancy:"serous ovarian tumours"
;[897..906]:malignancy:"neoplasms"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[780..783] The) (NN:[784..793] frequency))
      (PP (IN:[794..796] of)
        (NP
          (NP (NN:[797..803] Ki-ras) (NNS:[804..813] mutations))
          (PP-LOC (IN:[814..816] in)
            (NP (JJ:[818..824] serous) (JJ:[825..832] ovarian)
                (NNS:[833..840] tumours))))))
    (VP (VBZ:[841..846] seems)
      (S
        (NP-SBJ-1 (-NONE-:[846..846] *))
        (VP (TO:[847..849] to)
          (VP (VB:[850..859] correlate)
            (PP-CLR (IN:[860..864] with)
              (NP
                (NP (DT:[865..868] the) (JJ:[869..878] malignant)
                    (NN:[879..888] potential))
                (PP (IN:[889..891] of)
                  (NP (DT:[892..895] the) (NNS:[897..906] neoplasms)))))))))
    (.:[906..907] .)))

;sentence 8 Span:908..1093
;The data favour the hypothesis of a de novo development of poorly 
;differentiated ovarian carcinomas and do not support an evolution from LMP 
;tumours or well-differentiated carcinomas.
;[967..1008]:malignancy:"poorly  differentiated ovarian carcinomas"
;[1046..1058]:malignancy:"LMP  tumours"
;[1062..1092]:malignancy:"well-differentiated carcinomas"
(SENT
  (S
    (NP-SBJ (DT:[908..911] The) (NNS:[912..916] data))
    (VP
      (VP (VBP:[917..923] favour)
        (NP
          (NP (DT:[924..927] the) (NN:[928..938] hypothesis))
          (PP (IN:[939..941] of)
            (NP
              (NP (DT:[942..943] a)
                (ADJP (FW:[944..946] de) (FW:[947..951] novo))
                (NN:[952..963] development))
              (PP (IN:[964..966] of)
                (NP
                  (ADJP (RB:[967..973] poorly) (JJ:[975..989] differentiated))
                  (JJ:[990..997] ovarian) (NNS:[998..1008] carcinomas)))))))
      (CC:[1009..1012] and)
      (VP (VBP:[1013..1015] do) (RB:[1016..1019] not)
        (VP (VB:[1020..1027] support)
          (NP
            (NP (DT:[1028..1030] an) (NN:[1031..1040] evolution))
            (PP (IN:[1041..1045] from)
              (NP
                (NP (NN:[1046..1049] LMP) (NNS:[1051..1058] tumours))
                (CC:[1059..1061] or)
                (NP
                  (ADJP (RB:[1062..1066] well) (HYPH:[1066..1067] -)
                        (JJ:[1067..1081] differentiated))
                  (NNS:[1082..1092] carcinomas))))))))
    (.:[1092..1093] .)))

;section 9 Span:1097..1142
;PMID: 10071245 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1097..1101] PMID) (::[1101..1102] :) (CD:[1103..1111] 10071245)
        (NN:[1112..1113] -LSB-) (NNP:[1113..1119] PubMed) (::[1120..1121] -)
        (NN:[1122..1129] indexed) (IN:[1130..1133] for)
        (NNP:[1134..1142] MEDLINE-RSB-)))
